Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. 30087554 2018
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia. 28449314 2017
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. 29296758 2017
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 GeneticVariation disease BEFREE We aimed to screen exons 9-14 of the CD22 gene, which is a mutational hot spot region in B-precursor acute lymphoblastic leukemia (pre-B ALL) patients, to find possible genetic variants that could play role in the pathogenesis of pre-B ALL in Turkish children. 27486888 2016
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer. 27689397 2016
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 AlteredExpression disease BEFREE Characterization of CD22 expression in acute lymphoblastic leukemia. 25728039 2015
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE The anti-leukemic activity of this RTM against BPL xenograft clones derived from CD22ΔE12(+) leukemia patients provides the preclinical proof-of-concept that correcting the CD22ΔE12 defect with rationally designed CD22 RTMs may provide the foundation for therapeutic innovations that are needed for successful treatment of high-risk and relapsed BPL patients. 25567759 2015
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE HA22 is composed of an Fv that binds to CD22 fused to a portion of Pseudomonas exotoxin A. HA22 is very active in drug-resistant hairy cell leukemia but is less active in children with acute lymphoblastic leukemia. 23486472 2013
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE An immunotoxin (IT) constructed with RFB4, a murine anti-CD22 monoclonal antibody, and the "deglycosylated" A chain of ricin has shown activity at safe doses in patients with non-Hodgkin lymphoma and in children with acute lymphoblastic leukemia. 22327430 2012
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. 21348573 2011
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 Biomarker disease BEFREE We report on a case of a 30-year-old male with acute B-lymphoblastic leukemia (B-ALL) with immunophenotype CD19(+), CD22(+), CD20(+), CD10(+), with aberrant expression of CD13 and CD117, and IgH gene rearrangements. 19143872 2009
Precursor Cell Lymphoblastic Leukemia Lymphoma
0.100 AlteredExpression disease BEFREE All cases were confirmed as B-lineage lymphoblastic leukemia by virtue of expression of CD19 and/or CD22, lack of T-cell antigens, and lack of surface-membrane immunoglobulin (Ig). 1696310 1990